Dr. Daniel M. Anderson, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Minnesota Medical School (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 173
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: University of Minnesota Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MN license 42389 · WI license 46040
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Regions Hospital Saint PAul, MN
Medical groups
- Group Health Inc (1,638 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 173
- Services billed
- 572
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 153 | 95 |
| Insertion of needle into vein for collection of blood sample | 62 | 37 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 54 | 30 |
| Established patient office or other outpatient visit, 40-54 minutes | 48 | 25 |
| Blood creatinine level | 25 | 16 |
| New patient office or other outpatient visit, 60-74 minutes | 18 | 18 |
| New patient office or other outpatient visit, 45-59 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Saint PAul, MN | 137 |
| Oxycodone Hcl Other prescribers in Saint PAul, MN | 89 |
| Xtandi (enzalutamide) | 53 |
| Eliquis (apixaban) Other prescribers in Saint PAul, MN | 53 |
| Dexamethasone Other prescribers in Saint PAul, MN | 44 |
| Tamoxifen Citrate Other prescribers in Saint PAul, MN | 42 |
| Letrozole Other prescribers in Saint PAul, MN | 36 |
| Prednisone Other prescribers in Saint PAul, MN | 32 |
| Alendronate Sodium Other prescribers in Saint PAul, MN | 31 |
| Prochlorperazine Maleate Other prescribers in Saint PAul, MN | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $424,784 in research payments for these studies, mostly to the institutions running them.
- An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembro…
Merck Sharp & Dohme LLC - Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) …
E.r. Squibb & Sons, L.l.c. - Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06577441 - An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chem…
Ipsen Bioscience Inc. · NCT04083236 - Connect® MM- The Multiple Myeloma Disease Registry
E.r. Squibb & Sons, L.l.c. · Terminated · NCT01081028 - A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
Takeda Pharmaceuticals U.S.A., Inc. · Terminated · NCT03648372 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564
Merck Sharp & Dohme LLC - A phase 2 basket study of tucatinib in combination with trastuzumab in subjects with previously treated locallyadvanced unresectable or metastatic solid tumors driven by HER2 alterations
Pfizer Inc. - A Phase 3, randomized, double-blind trial of pembrolizumab MK-3475 with or without lenvatinib E7080,MK-7902 in participants with treatment-na ve, metastatic nonsmall cell lung cancer NSCLC whose tumors have a tumor pr…
Merck Sharp & Dohme LLC - A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
Ipsen Bioscience Inc. · Completed · NCT04083235
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.